Sandoz Group AG (XSWX:SDZ) Other Long Term Assets: CHF961 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SDZ Sandoz Group AG XSWX:SDZ
11 GF Score
Price CHF68.14
! 3 Warning Signs
View Full Analysis

What is Sandoz Group AG Other Long Term Assets?

Sandoz Group AG XSWX:SDZ +6.04% 11 Other Long Term Assets is CHF961 Mil as of Dec. 2025. GuruFocus rates XSWX:SDZ with a GF Score™ of 11/100. The stock has 3 warning signs investors should review.

Sandoz Group AG's other long-term assets for the quarter that ended in Dec. 2025 was CHF961 Mil.

Sandoz Group AG's quarterly other long-term assets declined from Dec. 2024 (CHF1,047 Mil) to Jun. 2025 (CHF1,013 Mil) but then stayed the same from Jun. 2025 (CHF1,013 Mil) to Dec. 2025 (CHF961 Mil).

Sandoz Group AG's annual other long-term assets increased from Dec. 2023 (CHF741 Mil) to Dec. 2024 (CHF1,047 Mil) but then declined from Dec. 2024 (CHF1,047 Mil) to Dec. 2025 (CHF961 Mil).

Sandoz Group AG Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Other Long Term Assets Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
732.24 741.13 1,046.74 961.06

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long Term Assets Get a 7-Day Free Trial 741.13 870.56 1,046.74 1,013.25 961.06
XSWX:SDZ
11GF Score
Sandoz Group AG XSWX:SDZ
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of CHF961 Mil mean?
Sandoz Group AG (XSWX:SDZ) has a Other Long Term Assets of CHF961 Mil as of Dec. 2025. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Other Long Term Assets too high?
Sandoz Group AG's current Other Long Term Assets is CHF961 Mil. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Other Long Term Assets compare to ZTS and UTHR?
Sandoz Group AG's Other Long Term Assets of CHF961 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Other Long Term Assets is CHF961 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current Other Long Term Assets of CHF961 Mil. The current Other Long Term Assets is CHF961 Mil. Sandoz Group AG's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Other Long Term Assets is CHF961 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score

Get the complete analysis for XSWX:SDZ

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF68.14
Price